Inactive Instrument

pSivida Co. Share Price Australian S.E.

Equities

Duration

Period

Style

EyePoint Pharmaceuticals Announces Third Quarter Fiscal Year 2018 Financial Results Release Date and Conference Call Information	19/18/19	GL
EyePoint Pharmaceuticals Strengthens Global IP with Notices of Allowance for Two U.S. Patents Related to DEXYCU™	12/18/12	GL
PSivida Corp. Announces Transformative Acquisition of Icon Bioscience Inc. and Growth Capital Financing with Essex Woodlands Healthcare Partners – Company Will Rebrand as EyePoint Pharmaceuticals, Inc.	29/18/29	GL
PSivida Announces FDA Acceptance For Filing of New Drug Application (NDA) for Durasert™ Three-Year Treatment for Posterior Segment Uveitis	19/18/19	GL
PSivida To Present at the 30th Annual ROTH Conference	05/18/05	GL

Sector